Clinical Report: Impact of Combining Meropenem and Ulinastatin on Inflammatory Responses
Overview
This study evaluates the effects of ulinastatin in addition to meropenem on inflammatory and clinical outcomes in severe septic shock patients. Results indicate differences in inflammatory markers, coagulation profiles, and complications in patients receiving the combination therapy.
Background
Septic shock is a critical condition with high morbidity and mortality, necessitating effective management strategies. The interplay of inflammation, coagulation, and immune response is crucial in determining patient outcomes.
Data Highlights
Outcome
Observation Group (n=53)
Control Group (n=53)
p-value
Overall Response Rate
90.6%
73.6%
< 0.05
CRP Levels
Lower
Higher
< 0.05
Fib Levels
Lower
Higher
< 0.05
Heart Rate Improvement
Greater
Lesser
< 0.05
ICU Stay Duration
Shorter
Longer
< 0.001
Complication Rate
9.4%
24.5%
< 0.05
Key Findings
The overall response rate was significantly higher in the observation group (90.6%) compared to the control group (73.6%).
Post-treatment inflammatory markers (CRP, PCT, IL-6, IL-8, TNF-α) were lower in the observation group.
Coagulation parameters (Fib levels, PT, APTT) showed improvement in the observation group.
Hemodynamic parameters (heart rate, MAP, cardiac index) improved more in the observation group.
ICU stay and mechanical ventilation duration were significantly shorter in the observation group.
The complication rate was lower in the observation group (9.4%) compared to the control group (24.5%).
Clinical Implications
The findings suggest differences in inflammatory and coagulation profiles between treatment groups, warranting further investigation.
Conclusion
The combination of ulinastatin and meropenem is associated with differences in outcomes in severe septic shock patients. However, due to the non-randomized nature of the study, causality cannot be definitively established.
